デフォルト表紙
市場調査レポート
商品コード
1513906

過敏性腸症候群（IBS）治療薬の世界市場

Irritable Bowel Syndrome (IBS) Therapeutics

出版日
ページ情報
英文 269 Pages
納期
即日から翌営業日
適宜更新あり
過敏性腸症候群（IBS）治療薬の世界市場
出版日: 2024年07月17日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 269 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

過敏性腸症候群（IBS）治療薬の世界市場は2030年までに34億米ドルに達する見込み

2023年に21億米ドルと推定される過敏性腸症候群（IBS）治療薬の世界市場は、分析期間2023-2030年にCAGR 7.2%で成長し、2030年には34億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるIBS-D治療薬は、CAGR 6.9%を記録し、分析期間終了までに19億米ドルに達すると予測されます。IBS-C治療薬セグメントの成長率は、分析期間中CAGR 7.5%と推定されます。

米国市場は5億6,590万米ドルと推定、中国はCAGR11.5%で成長予測

米国の過敏性腸症候群（IBS）治療薬市場は、2023年に5億6,590万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億9,180万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは11.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と7.4%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の過敏性腸症候群（IBS）治療薬市場- 主要動向と促進要因まとめ

過敏性腸症候群（IBS）は、大腸を侵し、腹痛、腹部膨満感、便秘、下痢などの症状を示す、一般的な胃腸疾患です。生命を脅かすものではないが、IBSは生活の質を大幅に低下させ、ヘルスケアシステムに大きな経済的負担を強いています。歴史的には、IBSは除外検査によって診断されてきたが、現在では、詳細な病歴聴取と身体診察に加え、Rome IIIのような基準を用いることで、より迅速な同定が可能となっています。この疾患は、腸の習慣の変化に伴う慢性の腹部不快感や腹痛を特徴とし、症状は診断の少なくとも6ヵ月前から始まり、過去3ヵ月間に1ヵ月に3日以上起こることが必要です。このような現代的な理解は、診断プロセスの合理化に役立ち、特に意図的でない体重減少や貧血などの重篤な指標を伴わない典型的なIBS症状を呈する若年患者において、不必要で費用のかかる検査を避けることができます。

IBSの治療法は年々多様化し、食物繊維補助食品や筋弛緩剤といった従来の選択肢にとどまらず、食生活の改善やプロバイオティクス、抗生物質、三環系抗うつ薬（TCA）や選択的セロトニン再取り込み阻害薬（SSRI）といった薬剤の組み合わせなど、主な症状に応じてオーダーメイドの治療が行われるようになっています。鎮痙剤は効果が限定的で副作用が大きいため、TCAやSSRIのような中枢と末梢の両方で痛みの知覚を調節する薬に重点が移りつつあります。さらに、食事管理、特に高FODMAP食物の削減とプロバイオティクスの使用は、腹部膨満感やその他の消化器系不快症状の管理に不可欠となっています。便秘や下痢を主症状とするIBSに対しては、便秘にはルビプロストンやリナクロチド、下痢にはアロセトロンやリファキシミンといった新しい薬剤が、障害の特定の機能的症状を標的とすることで治療効果を高めています。

IBS治療薬市場の成長を促す要因はいくつかあります。ローマIVガイドラインの施行など診断技術の進歩により、IBS診断の精度が向上し、より的を絞った治療アプローチが促進されています。また、メディアや患者支援団体、ヘルスケア・イニシアチブに後押しされる形で、消費者の意識と関与が高まり、効果的な治療法に対する需要が高まっています。遠隔医療サービスや症状追跡・管理のためのモバイルヘルスアプリケーションを含むデジタルヘルスソリューションの統合は、継続的な患者モニタリングと個別化された治療調整をサポートします。さらに、腸内細菌叢の修正を目的とした標的薬理学的薬剤の開発や、保険適用範囲の拡大、高額ではあるがより新しい治療を支持するヘルスケア政策により、これらの治療へのアクセスが向上しています。こうした進歩は、積極的な患者支援プログラムや規制状況の進化と並んで、IBS患者の増大するニーズに応え、その管理全般と生活の質を向上させるために不可欠なものです。

調査対象企業の例（全12件）

  • Allergan PLC
  • Astellas Pharma, Inc.
  • IM HealthScience
  • Mallinckrodt Pharmaceuticals
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6796

Global Irritable Bowel Syndrome (IBS) Therapeutics Market to Reach US$3.4 Billion by 2030

The global market for Irritable Bowel Syndrome (IBS) Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. IBS-D Therapeutics, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the IBS-C Therapeutics segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$565.9 Million While China is Forecast to Grow at 11.5% CAGR

The Irritable Bowel Syndrome (IBS) Therapeutics market in the U.S. is estimated at US$565.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$791.8 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Irritable Bowel Syndrome (IBS) Therapeutics Market - Key Trends and Drivers Summarized

Irritable Bowel Syndrome (IBS) is a prevalent gastrointestinal disorder that affects the large intestine, manifesting symptoms such as abdominal pain, bloating, constipation, and diarrhea. Although not life-threatening, IBS substantially reduces quality of life and imposes a significant economic burden on healthcare systems. Historically, IBS was diagnosed by exclusion, but advancements now allow for quicker identification using criteria such as the Rome III, alongside a detailed medical history and physical examination. This disorder is characterized by chronic abdominal discomfort or pain associated with altered bowel habits, with symptoms needing to have started at least six months before diagnosis and occurring at least three days per month in the last three months. This contemporary understanding helps streamline the diagnostic process, avoiding unnecessary and costly tests, especially in younger patients presenting typical IBS symptoms without severe indicators such as unintentional weight loss or anemia.

The treatment landscape for IBS has diversified over the years, moving beyond conventional options like fiber supplements and muscle relaxants to include tailored treatments based on predominant symptoms—ranging from dietary changes and probiotics to antibiotics and combinations of medications such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). There's a shifting emphasis from antispasmodics, due to their limited efficacy and significant side effects, towards TCAs and SSRIs that modulate pain perception both centrally and peripherally. Additionally, dietary management, particularly the reduction of high-FODMAP foods, and the use of probiotics have become integral in managing bloating and other digestive discomforts. For constipation and diarrhea predominant IBS, newer medications like lubiprostone and linaclotide for constipation, and alosetron and rifaximin for diarrhea, are enhancing therapeutic outcomes by targeting specific functional symptoms of the disorder.

Several factors are driving growth in the IBS therapeutics market. Advances in diagnostic technologies, such as the implementation of the Rome IV guidelines, have refined the accuracy of IBS diagnosis, fostering a more targeted therapeutic approach. There is also an increased consumer awareness and engagement, partly fueled by media, patient advocacy groups, and healthcare initiatives, which heighten demand for effective treatments. The integration of digital health solutions, including telehealth services and mobile health applications for symptom tracking and management, supports continuous patient monitoring and personalized treatment adjustments. Furthermore, the development of targeted pharmacological agents aimed at modifying gut flora, and expanding insurance coverage and healthcare policies that favor newer, albeit more costly, treatments are enhancing access to these therapies. These advancements, alongside active patient support programs and evolving regulatory landscapes, are essential for meeting the growing needs of IBS patients and improving their overall management and quality of life.

Select Competitors (Total 12 Featured) -

  • Allergan PLC
  • Astellas Pharma, Inc.
  • IM HealthScience
  • Mallinckrodt Pharmaceuticals
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Irritable Bowel Syndrome (IBS) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of IBS Propels Demand for Effective Therapeutics
    • Advances in Gut Microbiome Research Strengthen Business Case for Novel IBS Treatments
    • Increasing Awareness and Diagnosis of IBS Expands Addressable Market Opportunity
    • Focus on Personalized Medicine Drives Adoption of Tailored IBS Therapeutics
    • Growing Geriatric Population and Associated Digestive Disorders Spur Growth in IBS Therapeutics Market
    • Introduction of Combination Therapies Throws the Spotlight on Enhanced Treatment Efficacy
    • Advances in Probiotics and Prebiotics Propel Development of Innovative IBS Treatments
    • Increasing Focus on Non-Pharmacological Therapies: Here's the Story of Complementary Treatment Approaches
    • Focus on Minimizing Side Effects and Improving Quality of Life Sustains Demand for Novel Therapies
    • Growing Adoption of Digital Health Solutions Expands Access to IBS Treatment and Management
    • Advances in Molecular Diagnostics Propel Growth in Precision Medicine for IBS
    • Expansion of Telemedicine and Remote Patient Monitoring Drives Market Adoption
    • Advances in Drug Delivery Systems Propel Development of Novel IBS Therapeutics
    • Rising Prevalence of Lifestyle-Related Risk Factors Expands Addressable Market Opportunity
    • Development of Biosimilars and Generics Throws the Spotlight on Affordable Treatment Options
    • Increasing Focus on Integrative and Complementary Therapies Drives Demand for Comprehensive IBS Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for IBS-D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for IBS-D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for IBS-D by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for IBS-C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for IBS-C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for IBS-C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Linzess / Constella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Linzess / Constella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Linzess / Constella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Xifaxan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Xifaxan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Xifaxan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Viberzi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Viberzi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Viberzi by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Amitiza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Amitiza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Amitiza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • JAPAN
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • CHINA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • EUROPE
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • GERMANY
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • INDIA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030
  • AFRICA
    • Irritable Bowel Syndrome (IBS) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Type - IBS-D and IBS-C Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Type - Percentage Breakdown of Value Sales for IBS-D and IBS-C for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Irritable Bowel Syndrome (IBS) Therapeutics by Product - Percentage Breakdown of Value Sales for Linzess / Constella, Xifaxan, Viberzi, Amitiza and Other Products for the Years 2014, 2024 & 2030

IV. COMPETITION